Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

NCT ID: NCT01681693

Last Updated: 2014-10-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2013-07-31

Brief Summary

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.

Detailed Description

To investigate the potential association of polymorphic genetic variants MATE1 and OCT3 with altered response to metformin, a genotype to phenotype strategy is employed. Specifically, the investigators will evaluate this hypothesis in African-Americans, a population which has a high incidence of type 2 diabetes and which has high variant allele frequencies (44.5% for MATE1-66T>C and 11.3% in OCT3-81G>delGA) relative to other ethic groups. To assess the effects of these variants on metformin response, the investigators will measure metformin renal clearance (pharmacokinetics of metformin), and plasma glucose and insulin levels (pharmacodynamic response) in healthy and diabetic patients who carry either the reference or variant alleles.

Conditions

Healthy; Type 2 Diabetes Mellitus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Metformin

Subjects will be given an oral dose of metformin once per day for two days.

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Subjects will be given an oral dose of metformin once per day for two days.

Interventions

Metformin

Subjects will be given an oral dose of metformin once per day for two days.

Intervention Type: DRUG

Other Intervention Names

GLUCOPHAGE

Eligibility Criteria

Inclusion Criteria

• Subjects self-identify racial background, identify themselves, parents and four grandparents as African American
• Subject status is healthy volunteer from t In the event that diabetes is indicated in a normal subject based on OGTT results, we will notify the patients' primary care physician. he SOPHIE cohort OR diagnosis of T2DM based on American Diabetes Association (ADA) criteria
• Subjects over 18 years old and below 60 years
• Subjects who are healthy on the basis of medical history, physical examinations and laboratory tests if healthy volunteer from SOPHIE
• Subjects who agree with the written informed consent to participate in the study

Exclusion Criteria

• Unable to confirm African-American ethnicity
• Under 18 years old
• Pregnant or lactating women (female subjects will have a urine pregnancy test at the screening visit).
• Prior history of any allergic reaction to metformin
• Has a risk of congestive heart failure requiring pharmacologic treatment (medical history)
• Has a prior history of renal* or hepatic dysfunction (renal and hepatic function will be evaluated based on screening blood tests conducted prior to study enrollment)
• Risk of urinary or gastric retention or narrow-angle glaucoma (by medical history examination)
• Impaired renal function (e.g as suggested by abnormal creatinine clearance, eGFR <60 or serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction (heart attack), and septicemia, abnormal heart rhythms (tachyarrhythmias; heart beat > 100 beats per minute).
• Impaired hepatic function (> 1.5 times the upper limit of normal)
• Evidence of anemia (hemoglobin <10 g)
• Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine.
• They do not provide consent to participate in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of California, San Francisco

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kathleen M Giacomini, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

San Francisco General Hospital

San Francisco, California, United States

Countries

United States

Other Identifiers

6113

Identifier Type: -

Identifier Source: org_study_id